Please assess the completion status of the following clinical trial:

Trial Title: Neonatal Immunization With Pneumococcal Conjugate Vaccine in Papua New Guinea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~New born babies with birth weight \>2000 g (2 kgs) and parents giving consent~Exclusion Criteria:~1. Acute neonatal infection;~2. Severe congenital abnormality;~3. Children of mothers known to be HIV positive will be excluded;~4. Serious asphyxia at birth;~5. Intended migration in the next 2 years;~6. Parents withdraw consent;

- Gender: ALL
- Minimum Age: 1 Minute
- Maximum Age: 3 Days
- Healthy Volunteers: t

Study Arms:
- Neonatal 7vPCV (Type: EXPERIMENTAL): Receive study vaccine (Prevnar) at birth, 1 and 2 months
- Infant 7vPCV (Type: EXPERIMENTAL): Receive the study vaccine (Prevnar) at 1, 2 and 3 months
- Control (Type: PLACEBO_COMPARATOR): Do not receive study vaccine (Prevnar)

Based on this trial design, predict the completion outcome and termination type (if applicable).